Rebecca Silbermann, MD, MMS, discusses the findings of the phase 2 GRIFFIN study which were presented at the 2022 ASH Annual Meeting.
Rebecca Silbermann, MD, MMS, associate professor of medicine at the Division of Hematology/Medical Oncology at Oregon Health & Science University, discusses the findings of the phase 2 GRIFFIN study (NCT02874742) which were presented at the 2022 ASH Annual Meeting.
The study evaluated daratumumab (Darzalex) in addition to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (RVd) induction/consolidation therapy along with lenalidomide maintenance in patients with multiple myeloma.
Findings presented at ASH showed that the combination elicited a promising health-related quality of life benefit for patients with transplant eligible, newly diagnosed multiple myeloma.
Transcription:
0:08 | The GRIFFIN study is a large, randomized, phase 2 study of newly diagnosed myeloma patients who could receive either lenalidomide, bortezomib, dexamethasone, or lenalidomide bortezomib. dexamethasone with daratumumab. In the study, patients got 4 cycles of initial induction therapy, then went to stem cell transplant, had 2 cycles of post-transplant consolidation, and then went on to have maintenance therapy. This abstract was looking at patient reported outcomes that are based on surveys that they completed over the course of the study.
0:41 | What we found was that patients felt better over the course of treatment. We had reductions in fatigue, meaningful reductions in pain, improvements in patient's overall assessment of their quality of life, and there was a signal that there was even better improvement in patients symptoms for those who received daratumumab in combination with the lenalidomide, bortezomib, and dexamethasone. The surveys also continued throughout the maintenance phase of the studies and we were able to see how often patients felt they were getting worse. We found that most of the patients were not reporting worsening of their symptoms. We did not have a meaningful time to first worsening of symptoms themselves.
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More